Stockchase Opinions

Michael SmedleyNUCRYST Pharmaceuticals Corp.NCS.TODON'T BUYSep 24, 2007

Their acne treatment was not approved previously by the FDA, but suddenly was in July.. The approval isn’t doing a great deal for it.
$2.99

Stock price when the opinion was issued

biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

PAST TOP PICK
(A Top Pick Aug 24/06. Down 79.5%.) Their cream for treating acne did not get approved by the FDA, but did get approval 2 weeks ago. It might still be interesting. Sold his holdings.
PAST TOP PICK
(A Top Pick Aug 24/06. Down 52%.) Something went wrong with silver ointment treatment. They are back with silver bandaging. Based on the bandaging, it will be trading at 8-9 X earnings.
TOP PICK
The Silcryst bandaging spin off from Westaim (WED-T). (They still hold about 75%). Have developed/patented a technology for reducing nanotechnology silver to its crystalline level for application in ointments. Getting great revenues. Highly speculative.